{
    "title": "115_hr5801",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicaid Providers Are Required To \nNote Experiences in Record Systems to Help In-need Patients Act'' or \nthe ``Medicaid PARTNERSHIP Act''.\n\nSEC. 2. MEDICAID PROVIDERS ARE REQUIRED TO NOTE EXPERIENCES IN RECORD \n              SYSTEMS TO HELP IN-NEED PATIENTS.\n\n    (a) Requirements Under the Medicaid Program Relating to Qualified \nPrescription Drug Monitoring Programs and Prescribing Certain \nControlled Substances.--Title XIX of the Social Security Act (42 U.S.C. \n1396 et seq.) is amended by inserting after section 1943 the following \nnew section:\n\n``SEC. 1944. REQUIREMENTS RELATING TO QUALIFIED PRESCRIPTION DRUG \n              MONITORING PROGRAMS AND PRESCRIBING CERTAIN CONTROLLED \n              SUBSTANCES.\n\n    ``(a) In General.--Beginning October 1, 2021, a State shall, \nsubject to subsection (d), require each covered provider to check, in \naccordance with such timing, manner, and form as specified by the \nState, the prescription drug history of a covered individual being \ntreated by the covered provider through a qualified prescription drug \nmonitoring program described in subsection (b) before prescribing to \nsuch individual a controlled substance.\n    ``(b) Qualified Prescription Drug Monitoring Program Described.--A \nqualified prescription drug monitoring program described in this \nsubsection is, with respect to a State, a prescription drug monitoring \nprogram administered by the State that, at a minimum, satisfies each of \nthe following criteria:\n            ``(1) The program facilitates access by a covered provider \n        to, at a minimum, the following information with respect to a \n        covered individual, in as close to real-time as possible:\n                    ``(A) Information regarding the prescription drug \n                history of a covered individual with respect to \n                controlled substances.\n                    ``(B) The number and type of controlled substances \n                prescribed to and filled for the covered individual \n                during at least the most recent 12-month period.\n                    ``(C) The name, location, and contact information \n                (or other identifying number selected by the State, \n                such as a national provider identifier issued by the \n                National Plan and Provider Enumeration System of the \n                Centers for Medicare & Medicaid Services) of each \n                covered provider who prescribed a controlled substance \n                to the covered individual during at least the most \n                recent 12-month period.\n            ``(2) The program facilitates the integration of \n        information described in paragraph (1) into the workflow of a \n        covered provider, which may include the electronic system the \n        covered provider uses to prescribe controlled substances.\nA qualified prescription drug monitoring program described in this \nsubsection, with respect to a State, may have in place, in accordance \nwith applicable State and Federal law, a data sharing agreement with \nthe State Medicaid program that allows the medical director and \npharmacy director of such program (and any designee of such a director \nwho reports directly to such director) to access the information \ndescribed in paragraph (1) in an electronic format. The State Medicaid \nprogram under this title may facilitate reasonable and limited access, \nas determined by the State and ensuring documented beneficiary \nprotections regarding the use of such data, to such qualified \nprescription drug monitoring program for the medical director or \npharmacy director of any managed care entity (as defined under section \n1932(a)(1)(B)) that has a contract with the State under section 1903(m) \nor under section 1905(t)(3), or the medical director or pharmacy \ndirector of any entity has a contract to manage the pharmaceutical \nbenefit with respect to individuals enrolled in the State plan (or \nwaiver of the State plan). All applicable State and Federal security \nand privacy laws shall apply to the directors or designees of such \ndirectors of any State Medicaid program or entity accessing a qualified \nprescription drug monitoring program under this section.\n    ``(c) Application of Privacy Rules Clarification.--The Secretary \nshall clarify privacy requirements, including requirements under the \nregulations promulgated pursuant to section 264(c) of the Health \nInsurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d-2 \nnote), related to the sharing of data under subsection (b) in the same \nmanner as the Secretary is required under subparagraph (J) of section \n1860D-4(c)(5) to clarify privacy requirements related to the sharing of \ndata described in such subparagraph.\n    ``(d) Ensuring Access.--In order to ensure reasonable access to \nhealth care, the Secretary shall waive the application of the \nrequirement under subsection (a), with respect to a State, in the case \nof natural disasters and similar situations, and in the case of the \nprovision of emergency services (as defined for purposes of section \n1860D-4(c)(5)(D)(ii)(II)).\n    ``(e) Reports.--\n            ``(1) State reports.--Each State shall include in the \n        annual report submitted to the Secretary under section \n        1927(g)(3)(D), beginning with such reports submitted for 2023, \n        information including, at a minimum, the following information \n        for the most recent 12-month period:\n                    ``(A) The percentage of covered providers (as \n                determined pursuant to a process established by the \n                State) who checked the prescription drug history of a \n                covered individual through a qualified prescription \n                drug monitoring program described in subsection (b) \n                before prescribing to such individual a controlled \n                substance.\n                    ``(B) Aggregate trends with respect to prescribing \n                controlled substances such as--\n                            ``(i) the quantity of daily morphine \n                        milligram equivalents prescribed for controlled \n                        substances;\n                            ``(ii) the number and quantity of daily \n                        morphine milligram equivalents prescribed for \n                        controlled substances per covered individual; \n                        and\n                            ``(iii) the types of controlled substances \n                        prescribed, including the dates of such \n                        prescriptions, the supplies authorized \n                        (including the duration of such supplies), and \n                        the period of validity of such prescriptions, \n                        in different populations (such as individuals \n                        who are elderly, individuals with disabilities, \n                        and individuals who are enrolled under both \n                        this title and title XVIII).\n                    ``(C) Whether or not the State requires (and a \n                detailed explanation as to why the State does or does \n                not require) pharmacists to check the prescription drug \n                history of a covered individual through a qualified \n                drug management program before dispensing a controlled \n                substance to such individual.\n            ``(2) Report by cms.--Not later than October 1, 2023, the \n        Administrator of the Centers for Medicare & Medicaid Services \n        shall publish on the publicly available website of the Centers \n        for Medicare & Medicaid Services a report including the \n        following information:\n                    ``(A) Guidance for States on how States can \n                increase the percentage of covered providers who use \n                qualified prescription drug monitoring programs \n                described in subsection (b).\n                    ``(B) Best practices for how States and covered \n                providers should use such qualified prescription drug \n                monitoring programs to reduce the occurrence of abuse \n                of controlled substances.\n    ``(f) Increase to Federal Matching Rate for Certain Expenditures \nRelating to Qualified Prescription Drug Management Programs.--The \nSecretary shall increase the Federal medical assistance percentage or \nFederal matching rate that would otherwise apply to a State under \nsection 1903(a) for a calendar quarter occurring during the period \nbeginning October 1, 2018, and ending September 30, 2021, for \nexpenditures by the State for activities under the State plan (or \nwaiver of the State plan) to implement a prescription drug management \nprogram that satisfies the criteria described in paragraphs (1) and (2) \nof subsection (b) if the State (in this subsection referred to as the \n`administering State') has in place agreements with all States that are \ncontiguous to such administering State that, when combined, enable \ncovered providers in all such contiguous States to access, through the \nprescription drug management program, the information that is described \nin subsection (b)(1) of covered individuals of such administering State \nand that covered providers in such administering State are able to \naccess through such program. In no case shall an increase under this \nsubsection result in a Federal medical assistance percentage or Federal \nmatching rate that exceeds 100 percent.\n    ``(g) Rule of Construction.--Nothing in this section prevents a \nState from requiring pharmacists to check the prescription drug history \nof covered individuals through a qualified drug management program \nbefore dispensing controlled substances to such individuals.\n    ``(h) Definitions.--In this section:\n            ``(1) Controlled substance.--The term `controlled \n        substance' means a drug that is included in schedule II of \n        section 202(c) of the Controlled Substances Act and, at the \n        option of the State involved, a drug included in schedule III \n        or IV of such section.\n            ``(2) Covered individual.--The term `covered individual' \n        means, with respect to a State, an individual who is enrolled \n        in the State plan (or under a waiver of such plan). Such term \n        does not include an individual who--\n                    ``(A) is receiving--\n                            ``(i) hospice or palliative care; or\n                            ``(ii) treatment for cancer;\n                    ``(B) is a resident of a long-term care facility, \n                of a facility described in section 1905(d), or of \n                another facility for which frequently abused drugs are \n                dispensed for residents through a contract with a \n                single pharmacy; or\n                    ``(C) the State elects to treat as exempted from \n                such term.\n            ``(3) Covered provider.--\n                    ``(A) In general.--The term `covered provider' \n                means, subject to subparagraph (B), with respect to a \n                State, a health care provider who is participating \n                under the State plan (or waiver of the State plan) and \n                licensed, registered, or otherwise permitted by the \n                State to prescribe a controlled substance (or the \n                designee of such provider).\n                    ``(B) Exceptions.--\n                            ``(i) In general.--Beginning October 1, \n                        2021, for purposes of this section, such term \n                        does not include a health care provider \n                        included in any type of health care provider \n                        determined by the Secretary to be exempt from \n                        application of this section under clause (ii).\n                            ``(ii) Exceptions process.--Not later than \n                        October 1, 2020, the Secretary, after \n                        consultation with the National Association of \n                        Medicaid Directors, national health care \n                        provider associations, Medicaid beneficiary \n                        advocates, and advocates for individuals with \n                        rare diseases, shall determine, based on such \n                        consultations, the types of health care \n                        providers (if any) that should be exempted from \n                        the definition of the term `covered provider' \n                        for purposes of this section.''.\n    (b) Guidance.--Not later than October 1, 2019, the Administrator of \nthe Centers for Medicare & Medicaid Services, in consultation with the \nDirector of the Centers for Disease Control and Prevention, shall issue \nguidance on best practices on the uses of prescription drug monitoring \nprograms required of prescribers and on protecting the privacy of \nMedicaid beneficiary information maintained in and accessed through \nprescription drug monitoring programs.\n    (c) Development of Model State Practices.--\n            (1) In general.--Not later than October 1, 2020, the \n        Secretary of Health and Human Services shall develop and \n        publish model practices to assist State Medicaid program \n        operations in identifying and implementing strategies to \n        utilize data sharing agreements described in the matter \n        following paragraph (2) of section 1944(b) of the Social \n        Security Act, as added by subsection (a), for the following \n        purposes:\n                    (A) Monitoring and preventing fraud, waste, and \n                abuse.\n                    (B) Improving health care for individuals enrolled \n                in a State plan under title XIX of such Act (or waiver \n                of such plan) who--\n                            (i) transition in and out of coverage under \n                        such title;\n                            (ii) may have sources of health care \n                        coverage in addition to coverage under such \n                        title; or\n                            (iii) pay for prescription drugs with cash.\n                    (C) Any other purposes specified by the Secretary.\n            (2) Elements of model practices.--The model practices \n        described in paragraph (1)--\n                    (A) shall include strategies for assisting States \n                in allowing the medical director or pharmacy director \n                (or designees of such a director) of managed care \n                organizations or pharmaceutical benefit managers to \n                access information with respect to all covered \n                individuals served by such managed care organizations \n                or pharmaceutical benefit managers to access as a \n                single data set, in an electronic format; and\n                    (B) shall include any appropriate beneficiary \n                protections and privacy guidelines.\n            (3) Consultation.--In developing model practices under this \n        subsection, the Secretary shall consult with the National \n        Association of Medicaid Directors, managed care entities (as \n        defined in section 1932(a)(1)(B) of the Social Security Act) \n        with contracts with States pursuant to section 1903(m) of such \n        Act, pharmaceutical benefit managers, physicians and other \n        health care providers, beneficiary advocates, and individuals \n        with expertise in health care technology related to \n        prescription drug monitoring programs and electronic health \n        records.\n    (d) Report by Comptroller General.--Not later than October 1, 2020, \nthe Comptroller General of the United States shall issue a report \nexamining the operation of prescription drug monitoring programs \nadministered by States, including data security and access standards \nused by such programs.\n\n            Passed the House of Representatives June 19, 2018.\n\n            Attest:\n\n                                                 KAREN L. HAAS,\n\n                                                                 Clerk."
}